SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that the Company will participate in the Jefferies Global Healthcare Conference in London, being held November 16-19, 2026. Management will participate in a fireside chat on Wednesday, November 18, 2026, at 1:30 p.m. GMT / 8:30 a.m. ET. Intereste ...